RUA — Rua Life Sciences Income Statement
0.000.00%
Last trade - 00:00- £7.21m
- £4.73m
- £2.19m
- 21
- 51
- 77
- 46
Annual income statement for Rua Life Sciences, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.489 | 1.53 | 1.63 | 2.18 | 2.19 |
| Cost of Revenue | |||||
| Gross Profit | — | 1.25 | 1.36 | 1.79 | 1.78 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.43 | 3.08 | 3.98 | 4.49 | 4.13 |
| Operating Profit | -0.941 | -1.55 | -2.35 | -2.31 | -1.94 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.897 | -1.59 | -2.36 | -2.32 | -2.02 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.816 | -1.45 | -2.07 | -2 | -1.44 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.816 | -1.45 | -2.07 | -2 | -1.44 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.816 | -1.45 | -2.07 | -2 | -1.44 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.055 | -0.082 | -0.093 | -0.09 | -0.043 |